Hubei Biocause Pharmaceutical Net Asset Momentum
Hubei Biocause Pharmaceutical net asset momentum. Hubei Biocause Pharmaceutical (000627) recorded a net asset momentum of -2.8% as of December 2023, with net assets of CN¥33.63 Billion CNY. Net Asset Momentum measures the year-over-year percentage change in net assets (total assets minus total liabilities), indicating how rapidly the company is building or eroding its equity base. Explore Hubei Biocause Pharmaceutical capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
YoY Momentum
Current Net Assets
Years of Data
Country
Net Asset Momentum of Hubei Biocause Pharmaceutical (2000–2023)
Net asset momentum of Hubei Biocause Pharmaceutical from 2000 to 2023. This chart tracks Hubei Biocause Pharmaceutical's year-over-year net asset growth across 24 annual reporting periods from 2000 to 2023. The most recent momentum reading is -2.8%, with net assets of CN¥33.63 Billion CNY as of December 2023. See 000627 book value for net asset value and shareholders' equity analysis.
Hubei Biocause Pharmaceutical Net Asset Momentum by Year (2000–2023)
Hubei Biocause Pharmaceutical net asset momentum by year from 2000 to 2023. The table below shows the complete annual net asset history for Hubei Biocause Pharmaceutical from 2000 to 2023, covering 24 yearly periods. Each row includes total assets, total liabilities, net assets, and the year-over-year momentum figure for that period. For live market cap and overall valuation, see Hubei Biocause Pharmaceutical (000627) market capitalisation.
| Year | Net Assets (CNY) | Total Assets | Total Liabilities | YoY Momentum |
|---|---|---|---|---|
| 2023 | CN¥33.63 Billion | CN¥301.94 Billion | CN¥268.30 Billion | ▼ -2.8% |
| 2022 | CN¥34.60 Billion | CN¥288.60 Billion | CN¥254.00 Billion | ▼ -7.7% |
| 2021 | CN¥37.47 Billion | CN¥263.90 Billion | CN¥226.43 Billion | ▲ +8.3% |
| 2020 | CN¥34.59 Billion | CN¥239.40 Billion | CN¥204.81 Billion | ▲ +0.7% |
| 2019 | CN¥34.35 Billion | CN¥205.27 Billion | CN¥170.92 Billion | ▲ +32.1% |
| 2018 | CN¥26.01 Billion | CN¥178.25 Billion | CN¥152.24 Billion | ▼ -2.6% |
| 2017 | CN¥26.70 Billion | CN¥140.42 Billion | CN¥113.71 Billion | ▲ +30.9% |
| 2016 | CN¥20.40 Billion | CN¥117.88 Billion | CN¥97.48 Billion | ▲ +1043.5% |
| 2015 | CN¥1.78 Billion | CN¥2.41 Billion | CN¥625.50 Million | ▲ +19.7% |
| 2014 | CN¥1.49 Billion | CN¥2.11 Billion | CN¥618.76 Million | ▲ +3.7% |
| 2013 | CN¥1.44 Billion | CN¥2.16 Billion | CN¥720.71 Million | ▼ -6.6% |
| 2012 | CN¥1.54 Billion | CN¥2.06 Billion | CN¥527.37 Million | ▲ +8.7% |
| 2011 | CN¥1.41 Billion | CN¥1.88 Billion | CN¥469.47 Million | ▼ -11.7% |
| 2010 | CN¥1.60 Billion | CN¥1.98 Billion | CN¥374.25 Million | ▲ +1.8% |
| 2009 | CN¥1.57 Billion | CN¥2.16 Billion | CN¥581.29 Million | ▲ +4.1% |
| 2008 | CN¥1.51 Billion | CN¥1.98 Billion | CN¥466.75 Million | ▲ +74.7% |
| 2007 | CN¥866.03 Million | CN¥1.32 Billion | CN¥458.52 Million | ▲ +19.7% |
| 2006 | CN¥723.71 Million | CN¥1.17 Billion | CN¥443.66 Million | ▼ -1.0% |
| 2005 | CN¥731.23 Million | CN¥1.09 Billion | CN¥356.70 Million | ▲ +1.0% |
| 2004 | CN¥723.91 Million | CN¥1.08 Billion | CN¥357.41 Million | ▲ +0.7% |
| 2003 | CN¥718.75 Million | CN¥1.09 Billion | CN¥372.22 Million | ▼ -6.4% |
| 2002 | CN¥768.02 Million | CN¥1.09 Billion | CN¥322.39 Million | ▲ +0.7% |
| 2001 | CN¥762.99 Million | CN¥989.09 Million | CN¥226.09 Million | ▲ +28.3% |
| 2000 | CN¥594.52 Million | CN¥886.33 Million | CN¥291.81 Million | — |